Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$21 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.3
Industry P/E
--
EV/EBITDA
-2.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
73,180,045
CFO
$-60.44 Mln
EBITDA
$-66.94 Mln
Net Profit
$-69.62 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IceCure Medical (ICCM)
| -50.8 | -48.1 | -50.8 | -75.3 | -35.7 | -40.0 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
IceCure Medical (ICCM)
| -43.5 | -31.0 | -49.2 | 1,119.0 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IceCure Medical (ICCM)
|
0.3 | 20.5 | 3.4 | -15.1 | -446.7 | -188.8 | -- | 2.3 |
| 13.8 | 849.6 | 370.5 | 93.8 | 27.9 | 13.5 | 9.4 | 1.3 |
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and... internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel. Address: 7 Ha?Eshel St., Caesarea, Israel, 3079504 Read more
CEO & Director
Mr. Eyal Shamir
CEO & Director
Mr. Eyal Shamir
Headquarters
Caesarea
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of IceCure Medical Ltd (ICCM) is $0.30 (NASDAQ) as of 02-Apr-2026 19:58 EDT. IceCure Medical Ltd (ICCM) has given a return of -35.7% in the last 3 years.
Since, TTM earnings of IceCure Medical Ltd (ICCM) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of IceCure Medical Ltd (ICCM) are Rs 1.40 and Rs 0.28 as of 04-Apr-2026.
IceCure Medical Ltd (ICCM) has a market capitalisation of $ 21 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in IceCure Medical Ltd (ICCM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.